Bio-Techne (NASDAQ:TECH) Stock Unloaded Rep. April McClain Delaney

Representative April McClain Delaney (D-Maryland) recently sold shares of Bio-Techne Corp NASDAQ: TECH. In a filing disclosed on July 02nd, the Representative disclosed that they had sold between $1,001 and $15,000 in Bio-Techne stock on May 26th.

Representative April McClain Delaney also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of STERIS NYSE: STE on 6/26/2025.
• Purchased $1,001 - $15,000 in shares of Paychex NASDAQ: PAYX on 6/26/2025.
• Sold $1,001 - $15,000 in shares of Clean Harbors NYSE: CLH on 6/20/2025.
• Purchased $1,001 - $15,000 in shares of Tractor Supply NASDAQ: TSCO on 6/6/2025.
• Purchased $1,001 - $15,000 in shares of Markel Group NYSE: MKL on 6/6/2025.
• Sold $15,001 - $50,000 in shares of Fortune Brands Innovations NYSE: FBIN on 5/29/2025.
• Sold $1,001 - $15,000 in shares of Toro NYSE: TTC on 5/28/2025.
• Sold $1,001 - $15,000 in shares of Dayforce NYSE: DAY on 5/27/2025.
• Purchased $1,001 - $15,000 in shares of Markel Group NYSE: MKL on 5/27/2025.
• Purchased $1,001 - $15,000 in shares of Tractor Supply NASDAQ: TSCO on 5/27/2025.

Bio-Techne Trading Up 5.7%

NASDAQ:TECH traded up $3.16 on Thursday, hitting $58.47. 3,615,728 shares of the stock were exchanged, compared to its average volume of 1,997,496. The stock has a market cap of $9.17 billion, a PE ratio of 71.31, a PEG ratio of 2.54 and a beta of 1.39. The company has a current ratio of 3.71, a quick ratio of 2.58 and a debt-to-equity ratio of 0.16. The stock has a fifty day moving average of $50.63 and a 200-day moving average of $57.92. Bio-Techne Corp has a fifty-two week low of $46.01 and a fifty-two week high of $83.62.

Bio-Techne (NASDAQ:TECH - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biotechnology company reported $0.56 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.51 by $0.05. Bio-Techne had a return on equity of 13.17% and a net margin of 10.89%. The business had revenue of $316.18 million during the quarter, compared to analyst estimates of $317.92 million. During the same quarter last year, the firm earned $0.48 earnings per share. The company's revenue for the quarter was up 4.2% compared to the same quarter last year. As a group, equities analysts expect that Bio-Techne Corp will post 1.67 earnings per share for the current fiscal year.

Bio-Techne Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, May 30th. Shareholders of record on Monday, May 19th were paid a dividend of $0.08 per share. The ex-dividend date was Monday, May 19th. This represents a $0.32 annualized dividend and a yield of 0.55%. Bio-Techne's dividend payout ratio is presently 39.02%.

Bio-Techne announced that its Board of Directors has approved a stock buyback program on Wednesday, May 7th that permits the company to buyback $500.00 million in shares. This buyback authorization permits the biotechnology company to repurchase up to 6.5% of its stock through open market purchases. Stock buyback programs are typically a sign that the company's board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Scotiabank lowered their target price on Bio-Techne from $90.00 to $75.00 and set a "sector outperform" rating for the company in a research note on Friday, July 11th. Stephens upgraded Bio-Techne to a "strong-buy" rating and set a $65.00 target price for the company in a research note on Tuesday. TD Cowen assumed coverage on Bio-Techne in a research note on Wednesday, July 9th. They issued a "buy" rating and a $65.00 target price for the company. Royal Bank Of Canada lowered their target price on Bio-Techne from $72.00 to $63.00 and set a "sector perform" rating for the company in a research note on Thursday, May 8th. Finally, Wall Street Zen lowered Bio-Techne from a "buy" rating to a "hold" rating in a research note on Sunday, June 8th. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $69.58.

Institutional Trading of Bio-Techne

Several large investors have recently added to or reduced their stakes in TECH. CX Institutional acquired a new position in shares of Bio-Techne in the 1st quarter worth $27,000. AlphaQuest LLC acquired a new position in shares of Bio-Techne in the 1st quarter worth $34,000. Itau Unibanco Holding S.A. acquired a new position in shares of Bio-Techne in the 4th quarter worth $41,000. Federated Hermes Inc. acquired a new position in shares of Bio-Techne in the 1st quarter worth $41,000. Finally, GeoWealth Management LLC acquired a new position in shares of Bio-Techne in the 4th quarter worth $43,000. 98.95% of the stock is currently owned by institutional investors and hedge funds.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland's 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027. McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland's 6th Congressional District. She declared candidacy for the 2026 election. April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor's degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.